[4] [5] The standard of care remains disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs like methotrexate as first-line therapy, with escalation to biological DMARDs or targeted synthetic DMARDs if disease activity remains inadequately controlled, following a treat-to-target approach
Table 1: Snapshot of GLP-1 therapeutic indications currently approved conditions and those under clinical investigation or registration
Despite these gaps, GLP-1s are being prescribed more often to people with PWS
Wegovys introductory list price was over $1,300, making these drugs financially inaccessible for many people in these communities
Temperature excursions above 8C cause peptide aggregation, which reduces bioavailability and receptor binding affinity
Telephone or video consultation Simple and convenient access from anywhere in Portugal